Solentim Wins Two Queen’s Awards for Enterprise

Solentim’s business excellence and expertise in cell line development recognised with awards, for both International Trade and Innovation
8th October 2018

Solentim Queen's Awards

Wimborne, UK, 8th October 2018 / Sciad Newswire / Solentim, a leading provider of instrumentation used by biopharma companies in the fields of mammalian cell line development and cell culture, has received two Queen’s Awards for Enterprise, one for International Trade and one for Innovation. 

The Queen’s Awards for Enterprise are the UK’s most prestigious business awards, given only to companies or individuals seen as outstanding in their field. Awards are presented for International Trade, Innovation, Sustainable Development and Enterprise Promotion. 

HM Lord-Lieutenant of Dorset, Angus Campbell, presented the awards at an exclusive event on Thursday afternoon at Solentim’s Global Headquarters in Wimborne, followed by a keynote speech given by Dr Mark Stockdale, Group Leader, Applied R&D at Horizon Discovery. 

Upon receiving both awards, Aaron Figg, Co-Founder and Director of Solentim, commented “These awards truly reflect our commitment to commercial sales excellence and innovation, which are, and remain, key drivers for the success of the company; we are thrilled to receive these accolades. Solentim continues to facilitate the discovery and development of new biological drugs by our significant worldwide customer base, delivering the highest standards to achieve positive results, and I am delighted to see this recognised by the awards today”. 

These awards acknowledge Solentim’s commitment to delivering transformative approaches to aid the discovery and development of biological medicines, streamlining customer workflows and facilitating the improvement of the patient treatment landscape in a broad range of therapy areas. Solentim now provides a unique portfolio of products, including VIPS™, the Cell Metric® and the Clonality Report, which integrate together forming a simple to use solution for cell line development customers globally.

Solentim will also be sponsoring the Oxford Global 7thAnnual Cell Culture & Bioprocessing Congress in London this month. At the Congress, one of Solentim’s customers, Netherlands-based Genmab, will present data from their own use of the VIPS. Please get in touch to arrange a meeting. 

Ends

For further information, contact: 

Corporate Contact:
Ian Taylor, Sales & Marketing Director
Solentim Ltd
T: +44 (0)1202 051813
E: ian.taylor@solentim.com

PR Contact
Deborah Cockerill / Juliette Craggs
Sciad Communications Ltd
T: +44 (0)20 7470 8801
E: solentim@sciad.com 

Notes to Editors
Solentim enables its life science industry customers to develop a greater number of more effective pharmaceuticals to help patients live healthier, for longer. We do this through designing and manufacturing highly innovative instruments that facilitate the process of commercial cell line development. This phase of biopharmaceutical production is a high-value process which is intrinsically expensive and time-consuming. Our solutions significantly shorten the upstream cell line development workflow process and therefore make drug production faster and more cost effective. Our products; Cell Metric® and VIPS™ represent the next generation of single cell printing and provide documented proof of monoclonality for the FDA and other regulatory bodies. Five of the world’s top ten pharmaceutical companies use Solentim products. Established in 2010 and with global headquarters in Dorset, UK; the organisation employs over 40 people across the UK, Europe, Asia and the USA.

Photo (L to R): Aaron Figg, Dave Elverd, Mr (Ian) Angus Campbell (Her Majesty’s Lord-Lieutenant of Dorset), Ian Taylor, Sky Jiang. More photographs available on request.